Clinical trial
A Phase 1 Safety and Immunogenicity Study of the Pharmexa-Epimmune HIV-1 CTL Epitope-Based DNA Vaccine (EP HIV-1090) Administered Using a Biojector 2000 Needle Free Immunization Device in HIV-1 Infected Individuals Receiving Potent Combination Antiretroviral Therapy (ART)
NCT00532974 is registered in ClinicalTrials.gov with Epimmune as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Safety and Immunogenicity Study of the Pharmexa-Epimmune HIV-1 CTL Epitope-Based DNA Vaccine (EP HIV-1090) Administered Using a Biojector 2000 Needle Free Immunization Device in HIV-1 Infected Individuals Receiving Potent Combination Antiretroviral Therapy (ART)
- Lead sponsor
- Epimmune
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- October 31, 2006
- Completion date
- April 30, 2008
- Enrollment
- 32 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.